

CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Most recent changes to the CPT[®] Category I New Immunization* Vaccine Codes Long Descriptor document:

- Revision of 1 Category I code (91304) and addition of 6 Category I codes (90480, 91318, 91319, 91320, 91321, 91322) accepted by the CPT Editorial Panel. New codes 90480, 91318, 91319, 91320, 91321, 91322, revised code 91304, and all related references will be published in CPT 2025. Guidelines and parenthetical notes are only effective for codes that have received FDA Emergency Use Authorization (EUA) approval.
- Deletion of 64 Category I codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A, 91300, 91301, 91302, 91303, 91305, 91306, 91307, 91308, 91309, 91310, 91311, 91312, 91313, 91314, 91315, 91316, and 91317 accepted by the CPT Editorial Panel.
- Deletion of Appendix Q table.

*For the purposes of CPT coding, “Immunization” includes vaccines/toxoids, immune globulins, serum or recombinant products.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions” may result in gaps in code number sequencing.

The removal of the FDA pending symbol follows notification that this product had been granted FDA approval status on the date indicated. Code 90678 was originally published in CPT 2023.

Codes	Long Descriptor	Released to AMA Website	FDA Approval Effective	Publication
90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	June 30, 2023	May 31, 2023	CPT [®] 2024

The following vaccine codes were accepted at the July 2022 CPT Editorial Panel meeting for the 2024 CPT production cycle. These codes are effective immediately on July 26, 2022.

*Note that code 90611 will follow code 90713 and code 90622 will follow code 90627.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●90611	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use	July 26, 2022	July 26, 2022	CPT [®] 2024
#●90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use	July 26, 2022	July 26, 2022	CPT [®] 2024

The following vaccine codes were accepted at the February 2023 CPT Editorial Panel meeting for the 2024 CPT production cycle. Code 90679 was effective immediately on May 3, 2023. Codes 90589, 90623 are effective on January 1, 2024.

*Note that code 90589 will follow code 90586 and code 90623 will follow 90619.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
-------	-----------------	-------------------------	-----------	-------------

CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

#/●90589	Chikungunya virus vaccine, live attenuated, for intramuscular use	June 30, 2023	January 1, 2024	CPT [®] 2024
#/●90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	June 30, 2023	January 1, 2024	CPT [®] 2024
●90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	May 5, 2023	May 3, 2023	CPT [®] 2024

The following immunization codes were accepted at the May 2023 CPT Editorial Panel meeting for the 2024 CPT production cycle. Codes 90380, 90381 was effective immediately on July 17, 2023. Code 90683 is effective on January 1, 2024.

***Note that code 90683 will follow code 90679.**

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
✘●90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	June 30, 2023	July 17, 2023	CPT [®] 2024
✘●90381	1 mL dosage, for intramuscular use	June 30, 2023	July 17, 2023	CPT [®] 2024
#/●90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	June 30, 2023	January 1, 2024	CPT [®] 2024

The following immunization codes were accepted by the CPT Editorial Panel. Codes 90480, 91318, 91319, 91320, 91321, 91322 will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

***Note that code 90480 will follow code 90474 and codes 91304, 91318, 91319, 91320, 91321, 91322 will precede 90476.**

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose ▶ (Report 90480 for the administration of vaccine 91304, 91318, 91319, 91320, 91321, 91322) ◀ ▶ (Do not report 90480 in conjunction with 90476-90759) ◀	August 14, 2023	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2025
	▶ (0001A, 0002A, 0003A, 0004A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0051A, 0052A, 0053A, 0054A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀	August 14, 2023	November 1, 2023	CPT [®] 2025

CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

	<ul style="list-style-type: none"> ▶ (0121A, 0124A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0071A, 0072A, 0073A, 0074A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0151A, 0154A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0081A, 0082A, 0083A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0171A, 0172A, 0173A, 0174A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0011A, 0012A, 0013A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0064A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0134A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0141A, 0142A, 0144A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0091A, 0092A, 0093A, 0094A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0021A, 0022A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0031A, 0034A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0041A, 0042A, 0044A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0104A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0111A, 0112A, 0113A have been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ ▶ (0164A has been deleted. To report administration of COVID-19 vaccine, use 90480) ◀ 			
	<ul style="list-style-type: none"> ▶ (91300 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀ ▶ (91305 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀ ▶ (91312 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀ ▶ (91307 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] 	August 14, 2023	November 1, 2023	CPT [®] 2025

CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

<p>[coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91315 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91308 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91317 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91301 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91306 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91313 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91314 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91311 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91316 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91309 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91302 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p> <p>▶ (91303 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀</p>			
--	--	--	--

CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

#▲91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use ▶ (Report 91304 with administration codes 0041A, 0042A, 0044A) ◀	August 14, 2023	August 14, 2023	CPT [®] 2025
	▶ (Report 91304 with administration codes 90480, 0041A, 0042A, 0044A) ◀	August 14, 2023	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	
	▶ (91310 has been deleted. To report severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine product immunization, see 91318, 91319, 91320, 91321, 91322) ◀	August 14, 2023	November 1, 2023	CPT [®] 2025
#●91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use ▶ (Report 91318 with administration code 90480) ◀	August 14, 2023	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2025
#●91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use ▶ (Report 91319 with administration code 90480) ◀	August 14, 2023	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2025
#●91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use ▶ (Report 91320 with administration code 90480) ◀	August 14, 2023	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2025
#●91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use ▶ (Report 91321 with administration code 90480) ◀	August 14, 2023	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2025



CPT[®] Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

# 91322	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use</p> <p>▶ (Report 91322 with administration code 90480) ◀</p>	August 14, 2023	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2025
	<p>Appendix Q</p> <p>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines</p> <p>▶ The crosswalk of COVID-19 vaccine and administration codes and their associated patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses instructions (formerly Appendix Q) have been removed from the CPT code set. For information and guidance to report COVID-19 immunization services, refer to the E/M and Medicine section guidelines. ◀</p>	August 14, 2023	November 1, 2023	CPT [®] 2025